Zhejiang Orient Gene Biotech Co Ltd Total Liabilities
Zhejiang Orient Gene Biotech Co Ltd total liabilities. Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has total liabilities worth CN¥1.01 Billion CNY (≈ $148.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zhejiang Orient Gene Biotech Co Ltd (688298) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
Total liabilities of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024. This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TINC Comm VA
BR:TINC
|
Belgium | €35.74 Million |
|
Hangzhou Huasu Technology Co. Ltd. A
SHE:301157
|
China | CN¥193.58 Million |
|
Zhongjin Irradiation Incorporated Company
SHE:300962
|
China | CN¥481.47 Million |
|
HCM II Acquisition Corp. Unit
NASDAQ:HONDU
|
USA | $15.00 Million |
|
Goldiam International Limited
NSE:GOLDIAM
|
India | Rs-11.11 Billion |
|
Sunny Loan Top Co Ltd
SHG:600830
|
China | CN¥3.98 Billion |
|
Ambiq Micro, Inc.
NYSE:AMBQ
|
USA | $16.94 Million |
|
Northrim BanCorp Inc
NASDAQ:NRIM
|
USA | $3.07 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Zhejiang Orient Gene Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Zhejiang Orient Gene Biotech Co Ltd's balance sheet.
Liquidity & Leverage Metrics
Zhejiang Orient Gene Biotech Co Ltd Total Liabilities Ratios Explained
Zhejiang Orient Gene Biotech Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Orient Gene Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual total liabilities of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.30 Billion ≈ $190.69 Million |
-9.89% |
| 2023-12-31 | CN¥1.45 Billion ≈ $211.63 Million |
-39.25% |
| 2022-12-31 | CN¥2.38 Billion ≈ $348.38 Million |
+14.01% |
| 2021-12-31 | CN¥2.09 Billion ≈ $305.57 Million |
+86.14% |
| 2020-12-31 | CN¥1.12 Billion ≈ $164.16 Million |
+944.66% |
| 2019-12-31 | CN¥107.38 Million ≈ $15.71 Million |
-17.15% |
| 2018-12-31 | CN¥129.62 Million ≈ $18.97 Million |
+6.94% |
| 2017-12-31 | CN¥121.20 Million ≈ $17.74 Million |
-14.82% |
| 2016-12-31 | CN¥142.28 Million ≈ $20.82 Million |
-- |
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more